Alnylam Pharmaceuticals, Inc. Announces Sales Results for the Fourth Quarter and Full Year 2021
For the year, company reported Preliminary global net product revenues of $475 million, representing annual growth of 55% compared to full year 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
243 USD | -1.62% |
|
+46.65% | +26.95% |
1st Jan change | Capi. | |
---|---|---|
+26.95% | 30.74B | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |